# OnCo record nct05020236 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05020236/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05020236", "NCT05020236" ;
  schema:name "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments"@en ;
  schema:alternateName "MAGNETISMM-5"@en ;
  schema:description "A phase 3 trial of Elranatamab, Daratumumab, Pomalidomide in multiple myeloma, run by Pfizer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05020236/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05020236> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-10-04" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/elranatamab/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:companies <https://onco.cc/companies/pfizer/> .